Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRENASDAQ:ATHENASDAQ:FBLGNASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.79-1.1%$1.71$1.41▼$5.01$9.87M1.1822,481 shs4,878 shsATHEAlterity Therapeutics$4.57-1.6%$3.61$1.00▼$5.87$40.61M0.65142,794 shs2,537 shsFBLGFibroBiologics$0.74-1.7%$0.96$0.71▼$13.44$27.89M-0.25300,852 shs87,996 shsSCLXScilex$5.44-3.7%$6.12$3.60▼$80.50$37.06M1.161,134 shs29,738 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+4.34%+8.73%+6.18%-28.66%-61.60%ATHEAlterity Therapeutics+5.63%+10.19%+32.42%+15.92%+133.25%FBLGFibroBiologics-2.96%-12.79%-27.88%-40.48%-94.21%SCLXScilex+7.62%+20.73%+22.56%-31.60%-85.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.6864 of 5 stars3.54.00.00.03.82.51.3ATHEAlterity Therapeutics1.9689 of 5 stars3.33.00.00.02.31.70.0FBLGFibroBiologics2.6763 of 5 stars3.62.00.00.02.82.50.6SCLXScilex2.4716 of 5 stars3.33.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50768.35% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00162.87% UpsideFBLGFibroBiologics 3.20Buy$13.001,663.91% UpsideSCLXScilex 2.60Moderate Buy$455.008,265.51% UpsideCurrent Analyst Ratings BreakdownLatest APRE, FBLG, ATHE, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/11/2025SCLXScilexD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/2/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$770.00 ➝ $630.004/1/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/25/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.002/28/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$770.00 ➝ $770.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K17.02N/AN/A$4.54 per share0.39ATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AFBLGFibroBiologicsN/AN/AN/AN/A$0.04 per shareN/ASCLXScilex$50.71M0.75N/AN/A($1.10) per share-4.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$14.29M-$2.37N/AN/AN/A-1,029.50%-57.86%-47.94%8/11/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)FBLGFibroBiologics-$16.49M-$0.21N/AN/AN/AN/AN/A-225.34%8/6/2025 (Estimated)SCLXScilex-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%8/12/2025 (Estimated)Latest APRE, FBLG, ATHE, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/A3/31/2025Q4 2024FBLGFibroBiologics-$0.10-$0.09+$0.01-$0.09N/AN/A3/25/2025Q4 2024APREAprea Therapeutics-$0.69-$0.49+$0.20-$0.49$0.15 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A7.287.28ATHEAlterity TherapeuticsN/A3.543.54FBLGFibroBiologicsN/A1.231.23SCLXScilexN/A0.140.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%ATHEAlterity Therapeutics2.14%FBLGFibroBiologicsN/ASCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics12.80%ATHEAlterity Therapeutics38.80%FBLGFibroBiologics20.00%SCLXScilex7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.74 millionNo DataATHEAlterity Therapeutics108.87 million5.35 millionNot OptionableFBLGFibroBiologics1038.26 million28.84 millionN/ASCLXScilex806.95 million222.07 millionOptionableAPRE, FBLG, ATHE, and SCLX HeadlinesRecent News About These CompaniesScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FLMay 16, 2025 | globenewswire.comScilex adjusts director compensation post-stock splitMay 13, 2025 | investing.comScilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.May 1, 2025 | globenewswire.comScilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price RuleApril 30, 2025 | globenewswire.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025April 22, 2025 | globenewswire.comScilex Gets Orphan Drug Designation for Its Version of ColchicineApril 17, 2025 | marketwatch.comScilex treatment of pericarditis granted FDA orphan designationApril 17, 2025 | markets.businessinsider.comScilex confirms FDA awards orphan drug designation for colchicineApril 17, 2025 | markets.businessinsider.comScilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of PericarditisApril 16, 2025 | globenewswire.comScilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in CanadaApril 15, 2025 | globenewswire.comScilex announces 1-for-35 reverse stock splitApril 12, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Scilex Holding (SCLX)April 12, 2025 | msn.comScilex downgraded to Hold from Buy at D. Boral CapitalApril 11, 2025 | msn.comScilex Holding Company Announces 1-for-35 Reverse Stock SplitApril 11, 2025 | globenewswire.comScilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against AvevaMarch 26, 2025 | globenewswire.comScilex Holding Company Announces Change of Record Date for Preferred Stock DividendMarch 12, 2025 | nasdaq.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025March 10, 2025 | globenewswire.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025January 31, 2025 | globenewswire.comWhy Scilex Holding Co (SCLX) Stock is Currently 3.30% Above from Its 20-Day SMA?January 28, 2025 | bovnews.comScilex regains compliance with Nasdaq listing rulesJanuary 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, FBLG, ATHE, and SCLX Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.78 -0.02 (-1.11%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Alterity Therapeutics NASDAQ:ATHE$4.57 -0.08 (-1.62%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.FibroBiologics NASDAQ:FBLG$0.74 -0.01 (-1.73%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Scilex NASDAQ:SCLX$5.44 -0.21 (-3.73%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
